STAAR Surgical (NASDAQ:STAA) develops, manufactures, and markets implantable lenses for the eye, with a primary focus on vision correction solutions. Founded in 1987 and headquartered in Monrovia, California, the company pioneered the Implantable Collamer® Lens (ICL) platform. These biocompatible lenses are designed to address myopia, hyperopia, and astigmatism by providing an alternative to traditional glasses, contact lenses, and laser-based refractive procedures. STAAR Surgical’s portfolio includes the EVO and EVO+ Visian® ICL lenses, which have received regulatory approvals across multiple markets.
The core of STAAR Surgical’s offering is its Collamer® material, a proprietary biopolymer that integrates collagen to promote comfort and optical clarity. Beyond lenses, the company supplies surgical instruments, delivery systems, and support services to eye care professionals. STAAR also invests in ongoing clinical research to refine lens designs and expand indications, often collaborating with leading ophthalmic surgeons and academic institutions to validate long-term outcomes and safety profiles.
With a presence in over 75 countries, STAAR Surgical operates through direct sales offices in North America, Europe, Asia, and emerging markets, complemented by a network of distributors. The company holds CE Mark certification in Europe, FDA approval in the United States, and regulatory clearance in Japan, enabling its products to reach a diverse patient population. STAAR Surgical supports its global footprint with training programs, surgeon education initiatives, and local clinical support teams to ensure high standards of procedural success.
Leadership is headed by President and Chief Executive Officer Kerry L. Assil, who brings extensive experience in ophthalmology and medical device commercialization. Under his stewardship, STAAR Surgical continues to emphasize research and development, regulatory engagement, and market expansion to drive adoption of its ICL technology. The company’s strategic priorities include broadening clinical applications, enhancing manufacturing capabilities, and delivering innovations that address a growing global demand for refractive solutions.
